News & Updates
Filter by Specialty:
Pembrolizumab-based regimen continues to show favourable signals for ES-SCLC
In the long-term follow-up of the KEYNOTE-604 study, the combination regimen comprising pembrolizumab and etoposide/platinum (EP*) continued to demonstrate survival benefit as first-line therapy for patients with previously untreated extensive-stage small cell lung cancer (ES-SCLC).
Pembrolizumab-based regimen continues to show favourable signals for ES-SCLC
14 Oct 2022
Prexasertib works in select patients with recurrent ovarian cancer
CHK1 inhibition with prexasertib appears to have durable activity in some patients with recurrent ovarian cancer regardless of clinical characteristics, BRCA status, or prior therapies, according to the results of a phase II trial.
Prexasertib works in select patients with recurrent ovarian cancer
14 Oct 2022
Sotagliflozin may offer cardiorenal protection for adults with T1D
Using the Steno T1 Risk Engines, the dual SGLT*1 and SGLT2 inhibitor sotagliflozin showed potential in reducing the risk of cardiovascular (CV) and renal disease in adults with type 1 diabetes (T1D).
Sotagliflozin may offer cardiorenal protection for adults with T1D
13 Oct 2022
Early noninferior to delayed NOAC initiation after stroke in AF patients
Early initiation of nonvitamin K antagonist oral anticoagulants (NOACs) after acute ischaemic stroke in patients with atrial fibrillation (AF) appears to yield similar outcomes when compared with delayed initiation, as shown in the results of the TIMING* study.
Early noninferior to delayed NOAC initiation after stroke in AF patients
13 Oct 2022
Lebrikizumab efficacy in atopic dermatitis maintained at 1 year
Maintenance lebrikizumab monotherapy appears to improve outcomes in patients with moderate-to-severe atopic dermatitis (AD), according to results of the phase III ADvocate1 and ADvocate2 trials.